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Summary
Animal models are essential for understanding lymphoma biology and testing new treatments 
prior to human studies. Spontaneously arising lymphomas in pet dogs represent an underutilized 
resource that could be used to complement current mouse lymphoma models, which do not 
adequately represent all aspects of the human disease. Canine lymphoma resembles human 
lymphoma in many important ways, including characteristic translocations and molecular 
abnormalities and similar therapeutic responses to chemotherapy, radiation, and newer targeted 
therapies (e.g. ibrutinib). Given the large number of pet dogs and high incidence of lymphoma, 
particularly in susceptible breeds, dogs represent a largely untapped resource for advancing the 
understanding and treatment of human lymphoma. This review highlights similarities in molecular 
biology, diagnosis, treatment, and outcomes between human and canine lymphoma. It also 
describes resources that are currently available to study canine lymphoma, advantages to be 
gained by exploiting the genetic breed structure in dogs, and current and future challenges and 
opportunities to take full advantage of this resource for lymphoma studies.
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Rationale for a canine model of lymphoma
Representative animal models are critical for informing cancer biology research and 
developing new treatments. Research in lymphoma has benefited from traditional mouse 
models, but the lack of truly representative models has hindered full understanding of 
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disease biology and new drug development. However, the advent of genomics technologies 
has now made nontraditional animal models more accessible than ever before, and 
leveraging these new opportunities represents a strategy that could result in more rapid 
disease research and new drug discovery. Growing numbers of studies demonstrate that 
spontaneously arising lymphoma in pet dogs could be an invaluable resource to study the 
biology and treatment of this disease.
Traditionally, mouse cancer models have been either xenografts of human tumors into 
immunocompromised mice or have been genetically engineered mouse models (GEMMs) 
with lesions that result in increased and/or accelerated lymphoma incidence (1, 2). Both 
types of models have advantages and disadvantages. In xenograft models, the usual tumor 
environment is often not representative. As the importance of microenvironment and tumor-
stromal interactions becomes increasingly recognized in lymphoma, the deficiencies of this 
approach become more apparent. Another important limitation is the lack of a normal 
immune system, which is known to cause misrepresentative outcomes when treating any 
tumor type but which may be especially pertinent in the case of lymphoma, where cytokines 
and other lymphocyte signaling/survival factors are known to be involved in cell 
proliferation and survival. Therefore, while xenografts represent an excellent way to 
propagate human tumors, the ability to study detailed biologic mechanisms and treatment 
effects remains limited.
GEMMs are an improvement over xenograft models in that tumors arise in their native 
location and in the context of a normal murine immune system. However, GEMMs are 
limited by the necessity of knowing the specific genetic lesion(s) required to create the 
lymphoma-prone mouse, making them less useful for discovering the genetic origins of 
lymphoma. It also makes the mouse tumors more genetically homogeneous, which differs 
significantly from human tumors. Furthermore, mimicking particular lymphoma subtypes 
has been challenging with GEMM models. Hallmark translocations (IgH; CND1 in MCL 
and IgH; MYC in Burkitt lymphoma) have either not created increased rates of lymphoma 
and/or have not consistently produced the corresponding human lymphoma subtype in mice 
(1–3). Additional research should eventually overcome this problem, but until this can be 
achieved, complementary strategies are needed.
Pet dogs with spontaneously occurring lymphoma overcome many of the aforementioned 
challenges of murine models and also present additional advantages (4, 5). One advantage, 
from a drug development perspective, is that a large-animal model is essential for 
representative pharmacokinetic/pharmacodynamic (PK/PD) studies. It is well known that 
drug testing in mice and other small animals is often misleading since there are significant 
differences between rodent and human metabolism (6). Dogs, in contrast, are much larger, 
long-lived animals that are evolutionarily more closely related to humans than rodents (7). 
Lymphoma-bearing dogs would have the advantage of being able to ascertain PK/PD 
information while also getting information about efficacy of new drugs.
Another potential advantage of canine lymphoma is that their tumors arise spontaneously. 
This provides many opportunities not available with murine xenograft or GEMM models. 
First, the genetic diversity of canine tumors more accurately represents human tumors, as 
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does the (relative) age of onset. Therefore, the biology of canine tumors is more similar to 
spontaneously arising tumors in humans, allowing questions to be answered about tumor 
initiation and promotion that are impossible in engineered animal models. Second, the 
canine model harnesses the power of evolutionary conservation to identify similarities 
between canine and human lymphomagenesis, for example in identifying important ‘driver’ 
gene mutations that are common to both species.
Advantages of a canine model extend beyond the biological advantages of a spontaneously 
arising tumor in a large animal. First, since pet dogs share our environment, environmental 
risk factors can be studied in dogs as well as humans, strengthening the evidence for 
associations found in both species. Second, regulatory hurdles are less stringent for animal 
studies, allowing some procedures, such as serial tumor sampling, in dogs that would be 
difficult or impossible in humans. Third, the accelerated life cycle of dogs relative to 
humans allow studies to be completed more quickly, since lymphomas arise and recur in a 
shorter time frame. Finally, the breed structure of dogs, in association with well-annotated 
multi-generational pedigrees kept by many breeders, presents a distinct genetic advantage 
that allows the genetic mapping of lymphoma predisposition genes with strategies that are 
not possible in humans.
The final rationale for developing and using dogs as a model organism is a pragmatic one. 
The tumors that arise in dogs will continue to occur, whether we choose to study them or 
not. Exploiting this model may spare the creation and use of laboratory models, creating a 
‘win-win’ strategy to find improved treatments for pet dogs that can both improve 
understanding of the human disease via cross-species oncogenomics while improving 
veterinary cancer care (Fig. 1). This dual benefit to both humans and their best friends 
provides a powerful rationale for further development and study of the canine lymphoma 
model. In this review, we discuss in detail the mounting evidence that dogs are an accurate 
model for human lymphomagenesis and treatment to encourage the broader use and 
acceptance of this valuable resource for improving lymphoma care in both dogs and people.
Epidemiology of canine lymphoma and the growth of veterinary oncology
Similar to human non-Hodgkin lymphoma (NHL), canine lymphoma (CL) is a 
heterogeneous group of lymphoid malignancies that have different cells of origin and 
biological behaviors. The true incidence of CL is difficult to ascertain, since most dogs are 
diagnosed and treated by their local veterinarian and few are reported in the veterinary 
literature. In addition, most veterinary cancer registries have been short lived, with only four 
registries worldwide, to our knowledge, currently collecting information (8). Therefore, an 
estimate of the current incidence of the disease in the United States is based primarily on 
studies performed in the 1960s in California (9, 10). In these reports, CL accounted for 
~90% of all canine hematopoietic cancers. The incidence of CL was estimated at 21.7 cases 
per 100,000 dogs at risk, although more recent data from the U.K. suggest an increasing 
estimated age-adjusted incidence of up to 107 cases per 100,000 dogs at risk (11). With ~75 
million owned dogs in the United States, this suggests there are ~16–80,000 newly 
diagnosed cases of CL per year in the United States alone. These newer data imply that the 
incidence of CL is higher in dogs than in the human population, where the SEER age 
Richards and Suter Page 3






















adjusted incidence is 20.2 cases per 100,000 in 2011 (12). Indeed, the lifetime risk for CL in 
golden retrievers in the United States is ~1:8, compared with a lifetime risk for people of 
~1:50 (13). Importantly, the incidence of CL seems to be rising (14); it is now the second 
most frequent among all canine cancers after breast cancer. Supporting that these trends are 
also present in the U.S., a study of the Veterinary Medical Data Base Program (VMDP) at 
Purdue University found the rates of CL patients presenting to 27 North American 
veterinary teaching hospitals more than doubled between 1964 and 2002 (15). This mirrors 
human NHL, which has more than doubled in incidence since 1970, for reasons that are still 
unclear (12, 16, 17).
A variety of studies worldwide shows that certain dog breeds have a statistically significant 
increased risk of developing CL when compared to the average risk of all dogs (13, 15, 18–
22). This suggests that heritable risk factors for CL were introduced and/or perpetuated as 
specific dog breeds were developed over the past ~2800 years. Other evidence supporting 
this notion is the familial clustering observed in specific dog breeds, including Bullmastiffs, 
Rottweilers, and Scottish terrier lines (19, 21). In addition, there is a predilection for some 
dog breeds to develop specific subtypes of CL (Fig. 2). For example, although canine T-cell 
lymphomas (cTCL) account for 25%–35% of all CL, ~85% of all CL in boxers is comprised 
of cTCL, with >50% of these malignancies being CD3+CD4+ T cell in origin (23, 24). In 
addition, the risk of a boxer to develop CL is ~4 fold higher than the average risk of any 
dog. Most Asian dog breeds and the modern Spitz also develop cTCL almost exclusively. In 
contrast, basset hounds and cocker spaniels almost always develop B-cell lymphomas 
(cBCL), while golden retrievers tend to develop cTCL and cBCL at equal frequencies. 
Finally, mixed breed dogs develop cBCL and cTCL at a frequency (~70% cBCL and ~30% 
cTCL) similar to all purebred dogs when they are considered as a single group (25). This 
unintentional selection of deleterious genes that increase the susceptibility of purebred dogs 
to a variety of diseases, including CL, provides a unique and powerful opportunity to utilize 
modern molecular techniques to identify mutations that contribute to canine 
lymphomagenesis that may have direct applicability to human NHL.
Another important contribution to the field of canine CL (and canine cancer in general) has 
been the expansion of veterinary specialty care. There are currently >350 board-certified 
veterinary oncologists in the United States who have undergone 4 years of additional 
training after completing the standard veterinary curriculum. This has led to expansion in 
both the diagnostic capabilities for veterinary cancer patients and the available treatments. 
Most specialty practices have access to CT scans, MRIs, radioactive scanning, fluoroscopy, 
digital radiography, ultrasonagraphy, flow cytometry, clinical pathology, anatomic 
pathology, and, at some institutions, PET/CT scans and DEXA scanning to aid in diagnoses 
(26). Veterinary patients are able to tolerate chemotherapy regimens that are used in human 
patients, although the protocols are generally less dose-intense to ensure an adequate quality 
of life. Surgical oncology is a rapidly growing subspecialty in the veterinary field, and 
radiation therapy is available at many private practice facilities and academic institutions. As 
such, the expansion of the number of highly trained veterinary medical oncologists, surgical 
oncologists, and radiation oncologists has led to a multidisciplinary approach to veterinary 
cancer care that is very similar to physician-based medicine. The availability of 
sophisticated diagnostics has led to a dramatic increase in ability to stage veterinary patients 
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and, importantly, monitor treatment outcomes. Since veterinary cancer patients can be 
treated with the same treatment modalities that human patients are, they represent attractive 
large animal models to investigate novel treatment strategies.
Canine lymphoma subtypes and classification
Lymphomas in humans and dogs have many distinctive morphologic and 
immunophenotypic variants. A variety of histologic systems have been used to classify 
human NHL, and some of these have been applied to CL. Both the Kiel and Working 
Formulation (WF) systems categorize tumors as low-grade, intermediate-grade, or high-
grade (27, 28). Based on these two systems, the majority of CL are considered intermediate 
or high grade, although geographical differences were found; diffuse immunoblastic forms 
predominated in the United States, while follicular large cell variants predominated in 
Europe. Using both systems, low-grade tumors are characterized by small cells, a low 
mitotic rate, a slow clinical progression, and are considered incurable, while intermediate to 
high-grade tumors are characterized by large cells, a high mitotic rate, a rapid clinical 
progression, and are potentially curable (in humans).
In 1994, the Revised European American Classification of Lymphoid Neoplasms (REAL) 
was rapidly accepted and incorporated into The World Health Organization (WHO) 
classification of hematopoietic and lymphoid malignancies. The REAL-WHO system has 
also been adapted to include tumors in domestic animals, including CL (29). The REAL-
WHO system includes anatomic, histologic, and immunophenotypic data in an effort to 
provide an accurate and reproducible diagnosis for specific diseases. An additional benefit is 
an increased ability to do cross-species comparisons, detailing which histologic and 
immunophenotypic markers are conserved and which lymphoma subtypes are shared across 
species.
Based on the REAL-WHO system, the majority of CL are described as diffuse large B-cell 
lymphomas (DLBCL) (79%), with marginal zone lymphomas (MZL) a distant second (17%)
(20). In contrast to human lymphomas, follicular lymphoma (B-cell) in dogs is very rare 
(Fig. 3). With regards to T-cell malignancies, the two main subtypes are peripheral T-cell 
lymphoma-not otherwise specified (PTCL-NOS) (high-grade) and T-zone lymphoma (TZL)
(low-grade)(30). A wide variety of other B- and T-cell neoplasms exist, although they make 
up a small proportion of tumors that are commonly treated in the veterinary setting. Overall, 
~65–75% of CLs are B-cell malignancies, and ~25%–35% are T-cell malignancies (20, 31). 
This mirrors the situation in human NHL, where the majority are B-cell malignancies, with 
DLBCL being the most common subtype, and <15% are T-cell malignancies (32, 33).
Some human lymphoma subtypes are associated with viral infections, including human 
immunodeficiency virus (HIV), hepatitis C virus (HCV), human T-cell lymphotropic virus 
(HTLV), Kaposi sarcoma herpes virus (KSHV), and Epstein-Barr virus (EBV). There is 
mounting evidence that pet dogs may be infected with either EBV or an EBV-like 
gammaherpesvirus. A latent EBV or EBV-like gammaherpesvirus was detected in the 
peripheral blood and bone marrow of normal pet dogs in Taiwan (34), and antibodies to 
EBV or an EBV-like virus were detected in 38% of United Kingdom dog sera and 64% of 
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United States dog sera (35). More recently, the expression of EBV transcripts were detected 
in multiple canine tumors and the presence of classic herpesvirus virions were detected via 
electron microscopy in various tumors, including BL, in two separate reports (36, 37). Using 
PCR primers directed against a variety of specific EBV transcripts, our laboratory has also 
found that both canine lymphoid cell lines and clinical cases of CL harbor EBV or EBV-like 
genomic sequences (authors’ unpublished data). These combined data suggest that either 
EBV or an EBV-like virus has infected dogs and may be contributing, at least in part, to 
canine lymphomagenesis. If ultimately proven, canine BL could provide an extremely 
valuable animal model to better understand EBV-induced lymphomagenesis in both species.
Treatment of CL and clinical trials
Treatment modalities for CL are similar to those used for human lymphoma (radiation, 
corticosteroids, chemotherapy), but there are also important differences, both in available 
treatment modalities and in factors dictating treatment decisions. Incorporation of canine 
lymphoma trials into the human drug development pipeline will require an appreciation of 
these factors to appropriately design informative canine lymphoma trials.
Chemotherapy
The front-line treatment of choice for advanced stage CL, similar to human NHL, is CHOP-
based systemic chemotherapy (cyclophosphamide, doxorubicin, vincristine, and 
prednisone). Because FDA-approved chemotherapeutic agents are generally not labeled for 
use in dogs (so far there have only been two such drugs developed solely for a veterinary 
indication, neither known to be active in CL), the vast majority of drugs used by veterinary 
oncologists are based on human protocols and used off-label. Veterinary cancer 
chemotherapy in general has been developed only over the past 25 years with CL being the 
major focus, since it is one of the most chemo-sensitive malignancies in dogs (38) (Fig. 1).
There are a wide variety of studies showing that companion animals can tolerate most 
chemotherapeutic drugs given to human patients, and a complete review of these is beyond 
the scope of this article. However, some important general observations about companion 
animal chemotherapy based on these studies are notable. First, while the goal of most human 
chemotherapy protocols for aggressive lymphoma is to cure the patient (at the expense of 
significant toxicity), the usual goal of veterinary chemotherapy protocols is to extend an 
animal’s life and, at the same time, ensure a reasonable quality of life (QOL) during 
treatment. Therefore, veterinary protocols are less dose-intense, often only ~50% of the 
corresponding weight-based human dose, and are often given in smaller, more frequent 
doses (e.g. weekly instead of every 3 weeks) to decrease the associated toxicities. The vast 
majority of canine patients will not develop alopecia (except a few breeds such as poodles 
and Shih Tzus), and most dogs (and cats) enjoy an excellent QOL, with only minimal 
adverse events such a mild vomiting, diarrhea, anorexia, and/or febrile neutropenic episodes. 
With these less dose-intense protocols, malignancies such as CL are treatable, clearly 
extending life span, but incurable. Dogs with high-grade B-cell lymphoma have a median 
overall median of ~10–14 months (39, 40), whereas with no treatment, survival is ~6 weeks 
(41). The survival rate of CL using CHOP was ~20% of dogs at 2 years in one small study. 
(42)
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Dogs with high-grade T-cell lymphoma (PTCL-NOS), which is often associated with 
paraneoplastic hypercalcemia, tend to fare worse with CHOP-based chemotherapy 
protocols. In spite of achieving clinical remission rates with induction chemotherapy similar 
to dogs with B-cell CL (~85%), they have overall median survivals of only ~6–9 months 
(42). These worse outcomes in T- versus B-cell lymphomas mirrors outcome data in human 
T- and B-cell lymphoma (32, 33).
The only clinically relevant low-grade lymphoid malignancy in dogs is T-zone lymphoma 
(TZL), which has been described morphologically (30), clinically (43), and with gene 
expression profiling (GEP)(44). In one study examining canine TZL, the median survival 
time was 33.5 months, with no statistically significant difference between dogs treated with 
chlorambucil/prednisone or CHOP (43). This is a statistically significant longer median 
survival than in dogs with high-grade B- and T-cell tumors treated with CHOP.
In the same study, the authors suggest that canine B-cell marginal zone lymphoma (MZL) is 
also an indolent disease, as it is in human MZL, since a median survival of 21.2 months was 
reported. However, only 15 cases were identified, many of the cases were treated differently 
(or not at all), and this category included both splenic and nodal MZL. Recent GEP and 
immunohistochemistry analysis suggests that canine nodal MZL and DLBCL may, indeed, 
be the same disease (44, 45). In any case, MZL may be a misnomer since there are many 
dissimilarities between canine MZL and human MZL (e.g. canine MZLs are often CD10-
positive, and cells are large in size). Additional studies including larger numbers of dogs 
with nodal MZL are needed to clarify the origin of this lymphoma subtype.
Radiation
There are a variety of studies suggesting irradiation may be useful for the treatment of CL 
(46–48). More recently, a few non-randomized studies suggest the addition of external beam 
irradiation to a CHOP-based chemotherapy protocol is safe and, although not curative, may 
extend the lives of dogs with CL beyond the use of chemotherapy alone. All reported 
protocols utilize staged half-body irradiation given with a 2–4 week inter-fraction interval. 
The inter-fraction ‘rest’ allows recovery of the irradiated bone marrow so the other half of 
the body can be irradiated. Gustafson et al. (49) treated 6 dogs with CL using a half-body 
irradiation protocol (4 Gy two days in a row with a 4 week inter-fraction interval) interposed 
in a 25 week CHOP-based chemotherapy protocol and reported median remission and 
survival times of 455 and 560 days, respectively. Several other studies also suggested 
benefit from similar chemo/radiation approaches (50–52). Although protocols vary 
considerably, a variety of academic and private practice veterinary oncology practices offer 
half-body irradiation in conjunction with CHOP-based chemotherapy for the treatment of 
CL.
Monoclonal antibodies
Rituximab, a monoclonal antibody that recognizes the CD20 antigen universally present on 
mature B-cells, has been a major therapeutic advance in the treatment of all human B-cell 
NHL (53). However, rituximab is not useful to treat canine lymphomas because it does not 
recognize the canine CD20 protein (54). A murine monoclonal antibody raised using canine 
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CD20 extracellular domain peptide sequence specifically recognizes canine B cells and B-
cell lymphomas (55). Another canine anti-CD20 ‘caninized’ monoclonal antibody, AT-004, 
received a conditional license from the USDA for manufacture and distribution for the 
treatment of B-cell lymphoma in dogs (56). After preliminary studies showing improved 
overall survival compared to controls when given following chemotherapy, Novartis has 
licensed the product for commercialization. Another monoclonal antibody in the later stages 
of clinical development is AT-005. It recognizes CD52, the same antigen recognized by 
alemtuzumab (57), an antibody used to treat human TCL, and also has conditional approval 
from the USDA for the treatment of canine TCL (58). Other anti-lymphoma monoclonal 
antibodies recognizing antigens on lymphoma cells have demonstrated complement-
dependent cytotoxicity and antibody mediated cytotoxicity, as well as in vivo growth 
inhibition of lymphoma cells, indicating that therapeutic potential exists (55, 59–61). 
Several examples of cross-species epitope recognition by therapeutic monoclonal antibodies 
of both the canine and human orthologs have been demonstrated (60, 62), which 
demonstrate that in these cases, dogs could be used as pre-clinical models for human 
monoclonal antibody development.
Autologous transplantation
The pioneering canine experiments utilizing autologous (progenitor cells harvested from the 
patient) or allogeneic [progenitor cells harvested from a dog leukocyte antigen (DLA)-
matched donor] bone marrow transplants (BMT) to treat CL were performed in a research 
setting at the Fred Hutchinson Cancer Research Center. Drs. Joseph Murray and E. Donnall 
Thomas, who received the Nobel Prize in Medicine or Physiology in 1990 for this work, 
were utilizing dogs to study organ and cell transplantation for the treatment of human 
diseases. The large body of literature documenting these advances is beyond the scope of 
this review, nevertheless, based on this seminal work, the vast majority of human BMT 
protocols used today were perfected using normal dogs and dogs with CL. These early 
experiments showed that dogs could tolerate total body irradiation (TBI), that peripheral 
blood CD34+ cells could be harvested using sophisticated cell separator machines (63, 64), 
and that dogs given TBI could achieve complete hematologic reconstitution using either 
autologous (65, 66) or allogeneic (67) peripheral blood CD34+ cells. These studies also 
showed that dogs with CL could benefit from the addition of BMT to chemotherapy 
protocols (68, 69).
In more recent years, as veterinary care has become more sophisticated and cell separator 
machines have become available for clinical veterinary use, both autologous and allogeneic 
BMT are now options to treat CL. A variety of cell separator machines are able to harvest 
adequate numbers of canine peripheral blood CD34+ cells for BMT (70, 71), and dogs with 
CL will undergo complete hematologic reconstitution after otherwise lethal myeloablative 
therapy if given an appropriate dose of these cells (72, 73). Lupu et al. (70) described 
allogeneic BMT to treat a dog with relapsed T-cell CL that survived >19 months after 
diagnosis. Our group (74) treated 24 dogs with B-cell CL using autologous BMT and 
reported a median disease-free interval (DFI) and overall survival (OS) of all dogs from the 
time of BMT as 271 and 463 days, respectively. Thirty-three percent of these dogs lived > 2 
years post-BMT. Our group (75) also treated 15 dogs with T-cell CL using autologous BMT 
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and reported a median DFI and OS of the 13 dogs transplanted in first remission from the 
time of BMT as 184 and 240 days, respectively. Two of 13 (15%) dogs were alive 741 and 
772 days post-BMT. Finally, Frimberger et al. (76) used a CHOP-based protocol that 
utilized 3 different high-doses of cyclophosphamide and autologous BMT (to reduce bone 
marrow toxicities) to treat dogs with B- and T-cell CL and reported a median survival time 
for dogs receiving the highest dose of cyclophosphamide as 139 weeks, compared with 43 
weeks and 68 weeks for dogs in dogs receiving the lowest and intermediated dose of 
cyclophosphamide, respectively. At North Carolina State University, we have treated one 
dog with B-cell CL and one dog with acute large, granular lymphocytic leukemia using 
allogeneic BMT, and both dogs remain alive at 19 months and 26 months post-BMT, 
respectively (authors’ unpublished data). Both autologous and allogeneic BMT are currently 
offered by 4 private veterinary practices and 1 academic veterinary institution, although the 
costs of the procedure, at $16,000-$25,000, can be prohibitive to many pet owners.
Clinical trials
Comparing the efficacy of various veterinary chemotherapy protocols is limited, because 
most studies are statistically underpowered and/or do not utilize randomized, placebo 
controlled, prospective study designs. In addition, many published studies have inconsistent 
staging, inclusion, and response criteria. Finally, the majority of veterinary cancer patients 
do not die from their disease but are euthanized by their owners due to poor quality of life. 
This makes overall survival analysis much less robust than in human trials.
One final important observation is that the treatment of veterinary cancer patients and, 
therefore, prospective randomized trials, are dramatically influenced by finances. The vast 
majority of veterinary costs are paid out of pocket by owners, since veterinary insurance is 
rarely used. Therefore, veterinary oncologists must offer a variety of treatment protocols for 
a particular type of cancer based on cost rather than efficacy alone. Although this can be a 
difficult decision for pet owners, cost many times trumps efficacy. Another consideration is 
that most effective drugs used in veterinary oncology are unregistered off-label human 
generic (i.e. off-patent) drugs, so the incentive for sufficiently powered, randomized trials to 
study these agents is low.
To address some of these issues, the veterinary oncology community has moved forward 
with some important initiatives. In an effort to standardize response criteria and outcome 
reporting for future trials, the Veterinary Cooperative Oncology Group (VCOG) has 
published response evaluation criteria (77–79). In addition, to enable larger trials the 
Comparative Oncology Trials Consortium (COTC) was launched in 2009 through the 
intramural NCI’s Center for Cancer Research–Comparative Oncology Program (80, 81). 
The COTC, which is supported by the NCI, operates as a collaborative effort between the 
NCI and 20 extramural academic comparative oncology centers (Fig. 4). It functions to 
design and execute clinical trials in dogs with cancer in collaboration with the 
pharmaceutical industry and nongovernmental groups interested in cancer drug 
development. To ensure the integration of such biological endpoints in these studies the 
COTC Pharmacodynamic (PD) Core was also developed to provide infrastructure to support 
the development, validation, and assessment of pharmacokinetic, pharmacodynamic, and 
Richards and Suter Page 9






















biological endpoints within COTC trials (82). The first completed consortium trial published 
in 2009 (80) and a 12th trial is currently under development. Table 1 lists some examples of 
successful clinical trials with novel agents performed in dogs with CL.
As in human oncology, the clinical research organization (CRO) model aims to provide 
efficiency and facilitate partnering of pharmaceutical companies with veterinary hospital 
trial sites. The first example of a CRO in veterinary medicine is Animal Clinical 
Investigation (www.animalci.com). ACI provides regulatory strategy and preclinical 
planning, protocol design, and trial conduct at a multi-site network of oncology practices in 
the U.S. and Canada. They have performed over 30 clinical trials and are currently 
conducting trials with AT-005, an anti-CD52 antibody, with thalidomide, and with a 
thrombospondin-mimetic peptide (83).
Molecular similarities to human lymphoma
In addition to known clinical and histologic similarities, it is becoming increasingly apparent 
that canine lymphoma bears a striking resemblance to human lymphoma at the molecular 
level as well. These comparisons have become more nuanced as genomics tools have 
advanced, and many comparisons remain to be made. Still, findings to date reinforce the 
notion that human and canine lymphomas share significant similarity, while highlighting 
some differences as well.
Cytogenetics
Some of the first molecular comparisons between canine and human lymphoma were based 
on cytogenetic analyses. It is known that certain chromosomal alterations are recurrent in 
human lymphoma (84); some of these are highly enriched or even pathognomonic of the 
lymphoma subtype. These include t(8;14) in BL, t(11;14) in MCL, or t(14;18) in FL and 
DLBCL. Breen et al chose three regions of recurrent cytogenetic abnormalities and used the 
orthologous region in dogs to probe by fluorescence in situ hybridization (FISH).(85) Two 
of these abnormalities were hallmarks of B-cell malignancies [the t(8;14) in BL and deletion 
of p16 in chronic lymphocytic leukemia (CLL)], and the third was the Philadelphia 
chromosome [t(9;22), found in chronic myelogenous leukemia (CML)]. The Philadelphia 
chromosome [t(9;26) in dogs] was found in 2 dogs with CML and one with acute 
lymphoblastic leukemia (ALL). The translocation corresponding to t(8;14) was found in a 
BL case, and a p16Δ was in a CLL case, demonstrating for the first time genetic 
conservation between canine and human hematologic malignancies, both in the hallmark 
genetic aberrations and in the diseases associated with them.
DNA copy number
To comprehensively compare DNA copy number changes, array comparative genomic 
hybridization (aCGH) results were compared between canine and human lymphoma (86). 
There were notable differences in the degree of genomic instability between canine BCLs 
and TCLs; TCLs had more gains and losses than BCLs did. Interestingly, canine BCLs had 
many fewer areas of recurrent copy number changes than human BCLs. Recurrent canine 
BCL gains were seen on chromosome 13 and 31, corresponding to human chromosome 8 
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and 21, respectively. Losses were seen on chromosome 26. TCLs had gains on 
chromosomes 6, 9,13, 20, 29, 31, and 36, and losses of CFAs 11, 17, 22, 28, and 38. Gains 
on chromosomes 13 and 31 were common to both TCLs and BCLs. Importantly, these data 
were combined with human aCGH data to refine the results, narrowing the region on 
chromosome 13 to the syntenic region on human chromosome 8 containing the MYC gene, 
amplified in B-cell lymphomas from both species. This demonstrates that using two or more 
species, combined with mapping regions of synteny (87) allows finer resolution of important 
regions of gain/loss than are possible to resolve using single species data.
Gene expression profiling
Gene expression profiling (GEP) has played a major role in elucidating the biology of 
lymphoma subgroups as well as highlighting important prognostic signatures. In human 
DLBCL, GEP distinguishes two major subcategories based on cell of origin, the germinal-
center B-cell (GCB) and activated B-cell (ABC) subtypes (88). The ABC subtype is 
characterized by upregulation of the NF-KB pathway and poorer survival than the GCB 
subtype, which has a GEP profile reminiscent of other germinal-center derived cells, and a 
better prognosis than the ABC subtype. GEP platforms are now commercially available (e.g. 
Affymetrix, Agilent) and are being used to comprehensively characterize canine 
lymphomas.
In the first report demonstrating the utility of GEP in canine lymphoma, Frantz et al. (45) 
demonstrated that GEP could separate low-grade T-cell lymphomas, high-grade T-cell 
lymphomas, and B-cell lymphomas into separate groups. With a larger number of B-cell 
lymphoma samples, our group was able to separate canine B-cell lymphomas into two 
groups reminiscent of human ABC/GCB subtypes, in which the ABC-like subtype had a 
worse prognosis, similar to human DLBCL (44). We also showed that the ABC-subtype had 
higher expression of B-cell receptor and NF-KB pathway genes, as in human DLBCL. 
Similarly, Mudaliar et al. (89) found a signature of the NF-KB canonical pathway when 
comparing canine and human B-cell lymphomas. Additional studies with larger sample sizes 
and perhaps breed-specific studies will be needed to confirm and elaborate on these data, but 
initial similarities to human DLBCL are promising.
Another powerful use of canine GEP data is to combine it with human data in search of 
evolutionarily conserved similarities in the two data sets. This has been done in canine 
osteosarcoma, yielding predictive markers discovered only in the canine GEP data, which 
were nonetheless predictive when applied to human osteosarcoma samples. (90, 91) Our 
group demonstrated the power of cross-species oncogenomics in lymphoma when they 
combined gene expression data from cBCL and human DLBCL in a bivariate mixture 
model, yielding a robust small set (n=21) of differentially expressed genes common to both 
species that predicted survival in human DLBCL as accurately as a much larger set of genes 
(n=190) derived when human expression data alone was used (92) (Fig. 5). These examples 
demonstrate that cross-species comparisons can focus attention to the most biologically 
relevant genes in large data sets.
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Cellular markers: flow cytometry/IHC
A combination of cell surface markers, assessed by flow cytometry, and intracellular 
markers, assessed by immunohistochemistry, are used in both human and canine lymphoma 
to subclassify lymphomas. Identifying the correct subtype of lymphoma has important 
implications, both for further understanding biology, as well as clinically, to ensure the 
optimal treatment is administered. For the most part, canine lymphoma flow markers are 
those that have been validated in humans as clinically and/or biologically useful (e.g. CD 3, 
CD79a, CD4, CD8, CD21) to define cell of origin (lymphoid vs. non-lymphoid, B-cell vs. 
T-cell, mature vs. immature, etc.) for diagnostic purposes (93, 94).
One important use of IHC in human lymphoma is to subclassify DLBCL ABC and GCB 
subtypes. The Hans criteria were developed as a surrogate for GEP classification; by 
staining for CD10, BCL6, and MUM1 proteins, DLBCL can be classified into GCB and 
non-GCB subtypes (95). This classification has been shown to predict survival in numerous 
studies and has even been used to demonstrate differential outcomes in different treatment 
arms in several clinical trials (96–99). However, variability between laboratories makes this 
classification system unreliable. Several additional classification systems based on IHC have 
subsequently been developed attempting to improve robustness, but there are still significant 
barriers to using any of these in clinical practice (100). In canine lymphoma, both BCL6 and 
MUM1 are infrequently expressed. (44, 101) This makes application of the Hans criteria 
difficult, so alternative IHC schema will likely need to be implemented.
Another immunohistochemical prognostic system shown by several groups to be 
informative in DLBCL is staining for both MYC and BCL2. It has been recognized for years 
that double-hit lymphomas, with both c-MYC and BCL2 translocations, have an 
exceptionally poor prognosis. In addition, several recent studies have demonstrated that 
combined overexpression (an ‘immunohistochemical double hit’) is also a poor prognostic 
sign, albeit not as bad as the true cytogenetic double hit (102). This has been examined in 
canine lymphoma and also found to be true (103), strengthening the importance of these 
markers as indicators of lymphoma aggressiveness in both species.
Immunoglobulin genes
The immunoglobulin genes, encoding the B-cell and T-cell receptors, provide a unique way 
to identify clonality in lymphoma. Each individual cell has a unique immunoglobulin 
receptor that is produced (in B cells) by V-D-J gene selection and recombination, isotype 
switching, and somatic hypermutation (SHM). Studies of human lymphoma have not 
definitively demonstrated a bias in IGHV gene usage in DLBCL. However, cBCLs do have 
a bias in their IGHV usage; 31/52 cBCL tested used VH1-44, which is significantly different 
than in normal canine B lymphocytes. (104) Furthermore, dogs with cBCLs that use VH1-44 
have a longer overall survival. Intriguingly, VH1-44 is most closely homologous to human 
VH3-23, which is a commonly used VH gene in human DLBCL (10–15% of cases). It is not 
known whether usage of this gene is correlated with survival in human DLBCL.
Another feature of the immunoglobulin genes that is reported to be relevant to human 
DLBCL is the presence or absence of ongoing SHM. Nearly all human DLBCL have 
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undergone SHM, indicating they traversed the germinal center prior to lymphomagenesis. 
However, some DLBCL have high levels of SHM and intraclonal variability, leading to the 
hypothesis that the SHM machinery remains active, with ongoing SHM in these cells. 
Lossos et al. (105) analyzed a small number of DLBCL patients (n=14) and suggested that 
ongoing SHM is associated with the GCB subtype of DLBCL, while lack of ongoing SHM 
is associated with the ABC subtype. With a larger sample size, this correlation was not as 
strong in cBCL. More provocatively, in cBCL, presence or absence of ongoing SHM 
predicted survival more accurately than ABC/GCB subtype (44). Larger numbers of human 
DLBCL will need to be tested for ongoing SHM status to see whether this is also true in 
human DLBCL.
Oncogenic pathways
Aberrations in oncogenic pathways are the fundamental underpinnings of cancer 
phenotypes. These are shared in canine lymphomas in many cases. As more targeted 
therapies become available, understanding which genes are dysregulated and which are 
‘Achilles heels’ for a particular type of cancer becomes increasingly important. 
Conservation of mechanism is a particularly powerful strategy to identify these critical 
oncogenic changes. Several such changes have already been identified, demonstrating proof 
of principle.
FLT3
FLT3 is an important driver mutation in human acute myelogenous leukemia (AML) and is 
a negative prognostic marker (106). Rare cases of human ALL are also FLT3 positive. 
Similar to pediatric oncology incidence rates, canine AML is rare but ALL is more common. 
FLT3 mutations have been discovered in canine ALL, in the same characteristic internal 
tandem duplication that is mutated in humans ALL and AML (107). Furthermore, the same 
downstream signaling pathways are activated, and FLT3 inhibitors are efficacious against 
FLT3 mutant cells. Importantly, this establishes not only the same gene is affected in both 
species but also that the identical mutational mechanism occurs in both dogs and humans. 
This allows further study into both mutational mechanisms and their functional outcomes on 
aberrant oncogenic signaling.
NF-κB
The importance of the NF-κB pathway in human lymphoma is well established; NF-κB 
pathway members are constitutively upregulated in many malignancies and have been 
shown to be important for growth and survival of lymphoma cells (108). Cross-species 
conservation of aberrant NF-κB activation also supports its importance in lymphomagenesis 
and lymphoma growth/survival. Several studies have implicated the NF-κB pathway in 
canine lymphoma.
In the first large-scale study of gene expression profiling in canine lymphoma, we found two 
classes of canine B-cell lymphoma, based on human ABC and GCB subtypes in DLBCL 
(44). Separation into these two groups was improved when a ‘canine-specific’ ABC/GCB 
classifier was derived. The GCB-like subtype defined by this classifier had improved 
survival, analogous to human DLBCL. Furthermore, in the ABC-like subtype, genes in the 
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B-cell receptor pathway and the NF-KB pathway were overexpressed relative to the GCB-
like subtype, mirroring human DLBCL.
Mudaliar et al. (89) also examined gene expression profiling data, comparing normal and 
DLBCL-bearing lymph nodes in both dogs and humans, with a focus on NF-κB-related 
genes. Using expression levels of a literature-derived set of 120 NF-κB target genes, they 
demonstrated the ability in both human and canine samples to separate normal from tumor 
samples. Furthermore, using immunohistochemistry for p52 and p65 they demonstrated 
activation of both the alternative and canonical NF-κB pathway, respectively, in both canine 
and human DLBCL. Interestingly, the canine lymphoma samples had higher p52 (non-
canonical pathway) levels than p65 (canonical pathway) by immunohistochemistry, while in 
humans this was reversed. Drug sensitivity studies with these cell lines demonstrated 
sensitivity to an IKK inhibitor in both human and canine cells in vitro.
Functional relevance of NF-KB activation in canine lymphoma was demonstrated in two 
clinical trials of NEMO-binding domain peptide, a drug that inhibits NF-κB signaling (109, 
110). Eleven dogs with DLBCL and constitutive canonical NF-KB activity were treated with 
intravenous NBD peptide. NBD peptide was safe and blocked NF-KB activity in 6/10 dogs. 
Five dogs had >20% shrinkage after a single dose.
BCR pathway
Some of the most promising new drugs to treat human B-cell malignancies in recent years 
target the B-cell receptor pathway (111). One such agent, ibrutinib, has received expedited 
FDA approval for both mantle cell lymphoma and CLL (112). As part of the drug 
development pathway for this agent, it was tested in a veterinary trial for dogs with CBL 
(113). This study demonstrated responses in 3 of 8 dogs tested, with stable disease in an 
additional three dogs. No information about ABC/GCB status was available for these dogs, 
but it would be of interest to determine whether responses occur more often in the ABC 
subtype as has been shown in human DLBCL (99).
Bax/BCL2
Resistance to chemotherapeutic drugs is most likely due to resistance to apoptosis, since this 
is usually how neoplastic cells are killed by these agents (114). Since apoptosis is controlled 
by a family of both pro- and anti-apoptotic proteins of the BCL-2 family, it is possible that 
TCL cells have altered pro-/anti-apoptotic protein ratios that contribute to increased 
chemotherapy resistance and worse outcomes relative to BCL. Indeed, our laboratory has 
found that canine PTCL-NOS cells have a statistically significant reduced Bax (pro-
apoptotic):BCL-2 (anti-apoptotic) ratio when compared to neoplastic B-cells (manuscript in 
preparation). In addition, neoplastic canine T-cells have >300% increase in the expression of 
a microRNA (miRNA) cluster called miR-19 a+b when compared to normal canine 
peripheral blood mononuclear cells (115). MiR-19 a+b is part of the miR17-92 cluster 
(called oncomir-1), an oncogene acting primarily through inhibition of apoptosis (116). 
Interestingly, decreased expression of Bax has been identified in human TCL, CLL (114), 
and lymphoblastic leukemia, and reduced levels of Bax have also been implicated in 
resistance to therapy (117, 118).
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The p16/RB tumor suppressor pathway is inactivated in many tumor types in humans, 
including 50% of FL (119) and up to 66% of DLBCL (120), leading to RB phosphorylation 
and increased proliferation. Fosmire et al. (121) tested both T-cell and B-cell CL for 
deletion or promoter methylation of the p16 gene and RB phosphorylation. While deletion 
of p16 was restricted to high-grade TCL, high-grade BCL also showed increased RB 
phosphorylation (without p16 deletion), indicating alternative pathways of disrupting the 
p16/RB axis in these two tumor types. Likewise, aCGH results also confirm loss of the RB 
region, on canine chromosome 11, solely in cTCL (86). Furthermore, p16 loss and RB 
phosphorylation were both statistically significantly associated with survival in these dogs, 
which may partly reflect tumor type (T vs. B) and grade (high vs. low) (122).
Advantages unique to the canine model
To this point, we have stressed strategies to leverage the similarities between CL and human 
lymphoma. However, there are some advantages provided by canine models that are 
impossible to achieve in humans. These add to the already powerful rationale for utilizing 
the canine model in the study of human lymphoma.
One major advantage of dogs is the particularly high cancer susceptibility in certain breeds, 
implying a predisposition that can be genetically mapped (123). The genetic bottleneck and 
relatively short evolutionary time since breed divergence also creates much longer linkage 
disequilibrium blocks, resulting in a genome requiring many fewer SNPs to cover the 
genome, while maintaining very high power with fewer subjects than are needed in human 
genome wide association studies. It has been simulated that a simple Mendelian dominant 
trait could be found using only ~15,000 SNPs and 100 affected and 100 unaffected dogs, 
with >99% power (7). We have begun such a project to map the T-cell lymphoma 
susceptibility inherent in the boxer breed, with the hope that identification of the gene(s) will 
lead to greater insights about T-cell lymphomagenesis and potentially identify new 
treatments. Other phenotypes, such as particular cytogenetic abnormalities, lymphoma 
subtypes, or gene expression profiles, may also vary by breed, implying an underlying 
genetic predisposition that could be mapped, lending biologic insights that are not possible 
from a more heterogeneous human population.
Another advantage of studying lymphoma in dogs is that while it is similar in many ways to 
humans (spontaneously arising tumors, ability to perform clinical trials), ethical 
considerations differ. For instance, if needed, there is the capability to test biologic actions 
of drugs and other physiologically relevant phenomena in research dogs, using 
experimentally controlled conditions in a laboratory setting. Cadaver tissue from normal 
dogs, collected from dogs euthanized at shelters, is also more accessible, relative to humans. 
Permission for clinical trials comes from institutional animal use committees rather than 
institutional review boards governing human trials. This allows the focus to remain on the 
humane treatment of trial participants while eliminating some of the regulatory issues to 
which human trials are subject. Also important in this calculus is the fact that lymphoma in 
dogs is currently not curable, which creates a different risk/benefit ratio than in humans. 
This allows newer drugs to be moved earlier in the disease course and more flexibility in 
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experimental design (drug/chemo combinations, drug/drug combinations, window trials, 
etc.).
Resources available for further development of the CL model
One of the necessities for development of a new model organism is the development of 
research tools to accompany it. Genomics tools have seen rapid development over the past 
10 years, since the publication of the complete canine genome sequence. In combination 
with resources allowing wider access to tumor tissue and the ability to conduct clinical trials, 
the stage is set for rapid advancement of knowledge about canine lymphoma.
Experimental reagents
Canine lymphoid cell lines have been historically difficult to establish, and the number of 
well-characterized, available cell lines remains limited (Table 2). Even more limited are 
DLBCL cell lines. Only four of the available cell lines are reportedly of B-cell origin; GL-1 
was derived from a dog with B-cell ALL, 17-71 was not phenotyped initially and does not 
express typical B-cell lymphoma markers, and 3132 is likely not of B-cell origin despite 
initial reports of surface immunoglobulin (authors’ manuscript in preparation). Therefore 
only CBLB-1 appears to be potentially of DLBCL origin. One advantage to small numbers 
of cell lines is that they are well characterized (124), since they are repeatedly used within 
the canine research community. Better methods of propagating cells in vitro are also being 
developed. This will enhance our ability to perform short-term in vitro experiments using 
primary tumor cells and also be a potential route to improved rates of establishing 
immortalized canine lymphoma cell lines. One promising method has been the use of CD40 
ligand, allowing cell to proliferate up to 40 days (125).
The full genomic sequence of Canis lupus familiaris was published in 2005, and it was 
recently updated to cover 99.8% of the euchromatic region of the genome (7, 126). Having 
the full genomic sequence has allowed various sequence-based platforms to be 
commercially developed, including gene expression profiling chips, aCGH chips, SNP 
genotyping chips, and capture probes for whole exome sequencing (127).
Because lymphoid cell lines have been difficult to establish, alternative methods of 
propagating tumors have been developed. Xenografts into immunocompromised mice allow 
propagation of lymphoma specimens even in cases where cell lines cannot be established. 
Patient-derived xenografts are increasingly used to study human lymphoma, and are also 
being used in the study of canine lymphoma (128–132). This can potentially provide a wider 
variety of CL tumor types for in vivo studies.
The canine comparative oncology and genomics consortium (CCOGC) was formed to 
facilitate collaborations focused on understanding canine cancer. They formed a 
biospecimen repository in 2007, with current collection sites at six veterinary schools that 
provide samples from patients with seven common cancers, including lymphoma (5). They 
currently have over 2000 samples, which are available for scientific use.
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The One Medicine concept proposes that human and veterinary research are complementary 
approaches to the same problem. Although this idea is not new, human and veterinary 
medical collaborations embracing the joint advancement of medical knowledge is currently 
enjoying a renaissance, particularly in cancer research. The NCI has a Comparative 
Oncology Program (http://ccr.cancer.gov/resources/cop/default.asp), and most of the major 
veterinary schools have comparative oncology programs that partner with nearby medical 
schools for joint research possibilities. The growth of comparative oncology is also reflected 
in the growing number of journals, websites, and scientific meetings dedicated to the 
concept (133). The first meeting of the European canine lymphoma group was held in 2013, 
as a satellite meeting to the 12th International Conference on Malignant Lymphoma in 
Lugano, Switzerland, bringing together canine and human lymphoma experts (134).
Future challenges
Although our understanding of and interest in canine cancer models has increased 
tremendously, especially over the past 10 years, and infrastructure has been established, 
there are still challenges remaining. Continued research and development, as well as 
changing some well-established paradigm will be necessary to take full advantage this 
valuable resource for lymphoma research.
Drug development pipelines worldwide currently follow a common strategy: preclinical 
testing in cell lines and in mice, PK/PD testing in large animals (usually normal research 
dogs), and then phase I–III testing in human clinical trials. Under this paradigm, 85% of new 
agents fail in early stage clinical trials, and half that succeed fail to win FDA approval (135). 
Utilizing clinical trials in dogs as part of preclinical testing or in parallel with early stage 
human trials would make this process more efficient (Fig. 6). PK/PD studies routinely 
performed in normal research dogs could instead be performed in dogs with lymphoma, and 
efficacy data could be collected at the same time. Most academic veterinary institutions have 
the study personnel and facilities to perform phase I–III testing. These studies are potentially 
less expensive and more accurate than studies done with research dogs. Efficacy and toxicity 
data from canine trials could provide an early signal to complement data from human trials. 
Robust companion diagnostics and biomarkers of response could be developed in dogs, 
allowing earlier insertion into human clinical trials. One potential hindrance in this scenario 
is that some toxicities may be specific to dogs and not seen in humans. However, if this is 
monitored appropriately, more information from the canine model should augment rather 
than hinder drug development in humans (136).
Perhaps the largest hurdle to the widespread use of canine lymphoma as a model for the 
human disease is the lack of biologic/translational research data. As described in this article, 
research into the molecular underpinnings of canine lymphoma has just begun. Many more 
detailed studies are needed to determine which aspects of canine lymphoma biology will be 
best suited for modeling human lymphoma for drug development and other research 
purposes.
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Another hurdle (as in human trials) is the accessibility of clinical trials. This problem is 
exacerbated in veterinary medicine, since there are fewer than half as many veterinary 
schools (n=29) than there are NCI-designated cancer centers (n=68). Furthermore, many 
veterinary schools are located in rural areas; therefore the small animal caseload is limiting. 
To engage a large proportion of the U.S. pet population, creative ways to engage private 
practice veterinary oncologists will need to be explored. In addition, the advantages of 
participation in clinical trials (subsidized cost of treatment, access to novel agents, 
advancement of medical care for dogs and humans) will need to be disseminated to pet 
owners to encourage their support and participation.
Summary
Canine lymphoma is strikingly similar to the human disease in many respects and is 
currently an underutilized resource in the study of human lymphoma, particularly in the drug 
development pipeline. Recent advancements in our understanding of the molecular biology 
of canine lymphomas reinforce the cross-species conservation that we had expected based 
on histologic and clinical similarities. Exceptions to this, for example in 
immunohistochemical staining and gene expression profiling signatures, are being 
elucidated and will be important to understand both for advancing cancer biology 
knowledge and for accurate and appropriate use in targeted drug development. The 
appropriate clinical and biological resources are now in place to harness this resource, and 
increased utilization will depend on buy-in by pharmaceutical companies, community 
veterinary oncologists, and most importantly pet owners. The phrase ‘man’s best friend’ is 
now poised to take on a whole new meaning in the fight against cancer.
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Fig. 1. Veterinary oncology
(A). A dachshund with severely enlarged submandibular lymph nodes. This is one of the 
most common sites that CL presents clinically. (B). An English bulldog receiving 
intravenous chemotherapy. Most dogs do not need sedation during this procedure. (C). A 
diagnostic fine needle aspirate of the enlarged lymph nodes of the dog in (A), showing a 
monomorphic population of large, immature cells commonly seen in high-grade CL.
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Fig. 2. B-cell vs. T-cell lymphoma prevalence varies by breed
CL were phenotyped by BCR or TCR rearrangement, and percentages of each subtype (B 
vs. T) are shown. Breeds shown statistically significantly differ from one or both of the 
reference populations (mixed breed dogs or all study dogs as a group). Data are from 
Modiano et al. (13)
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Fig. 3. Canine B-cell lymphoma histologies
H&E and CD79a staining of canine lymph nodes showing different morphological patterns. 
CD79a is an intracellular antigen expressed by normal and neoplastic B cells. (A). Diffuse, 
large, B-cell lymphoma, the most common subtype of NHL in dogs. (B). Marginal zone 
lymphoma characterized morphologically by ‘fading germinal centers’. (C). Follicular 
lymphoma is rare in dogs.
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Fig. 4. COTC member institutions
The 20 current COTC sites are shown. They form a cooperative group network that conducts 
clinical trials in dogs with cancer (154).
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Fig. 5. Combined species data shows equivalent prognostic power with many fewer genes
The panel on the left uses human gene expression data only (190 genes) to distinguish 
groups with different survival times; on the right, human and canine data are combined to 
produce a more focused gene list (21 genes) with equivalent power to predict survival in 
human DLBCL. Numbers in parentheses are median survival times, in years. Figure 
reproduced from Su et al. (92)
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Fig. 6. Augmenting the drug development pipeline with lymphoma-bearing dogs
The current drug development pipeline uses normal research dogs for PK/PD studies. Pet 
dogs with lymphoma could be studied in earlier phase studies to refine PK/PD data and 
define biomarkers to be used for companion diagnostics (both predictive and target 
assessment biomarkers). Efficacy in both dogs and humans would reinforce the utility of 
agent, and earlier dog studies would allow more rapid adaptation if dosing/schedule/
endpoints needed to be modified.
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Table 1
Clinical trials using novel agents in CL.
Agent Tested Trial Type Size (n=) Results Reference
Elsamitrucin (topoisomerase II inhibitor) phase I
20 (10 with 
CL) MTD 0.08mg/kg; no objective responses
Fiocchi et al, 
2011(137)
Telomerase vaccine phase III 42
OS >76.1 wks with vaccine + chemo vs. 
29.3 weeks with chemo alone
Gavazza et al, 
2013(138)
Maitake mushroom extract phase II 15 no objective responses
Griessmayr et al, 
2007(139)
Nemo binding domain peptide (NF-KB 
inhibitor) phase I 11
7 dogs with CR; 1mg/kg maximally 
inhibits NF-KB without undue toxicity
Habineza 
Ndikuyeze et al, 
2014(110)
Autologous tumor microbead vaccine phase I 15 no change in PFS
Henson et al, 
2011(140)
KPT-335 (exportin 1 inhibitor) phase I
23 (20 with 
CL) stable disease or PR in 11/20 dogs
London et al, 
2014(141)
Heat shock protein peptide complex vaccine phase III 19
TTP 304 days with vaccine + chemo vs. 
41 days with chemo alone
Marconato et al, 
2014(142)
Patupilone (epothilone B) phase I
20 (6 with 
CL) MTD 2.76 mg/m2; no responses in CL
Meier et al, 
2013(143)
VDC-1101 (nucleotide analog, formerly 
GS-9219) phase I/II 38 ORR 79%; median TTP 128 days
Vail et al, 2009(60, 
144)
IMMU-114 (anti-HLA-DR antibody) pilot 6 2 of 6 dogs with transient response
Stein et al, 
2011(60)
ABT-751 (targets microtubules) phase I 30
MTD 350mg/m2; 3/15 (20%) ORR in 
expansion cohort
Silver et al, 
2012(145)
ABT-526 (thrombospondin peptide 
mimetic) phase III 94
ORR equal in two arms, but TTP in 
chemo + ABT-526 longer than chemo 
alone (41 vs. 15 days)
Rusk et al, 
2006(146)
PCI-32765 (ibrutinib, BTK inhibitor) pilot/phase I 8 3 PR, 3 SD; 20mg/kg dose tolerated
Honigberg et al, 
2010(113)
MTD: maximum tolerated dose; OS: overall survival; CR: complete response; PR: partial response; ORR overall response rate (CR+PR); TTP: 
time to progression
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Table 2
Canine cell lines.
Cell Line/Reference Derived From Phenotype Notable Features
GL-1 (107, 124, 147) B-cell leukemia IgH+, CD79a+, CD3− FLT3 ITD
UL-1 (132) ascites from renal lymphoma patient TCR+, IgH−, CD3−, CD21−
CL-1 (124, 148) pleural fluid from T-cell lymphoma patient TCR+, IgH−, CD3−, CD21− homozygous PTEN deletion
CLBL-1 (149) FNA from B-cell lymphoma patient TCR−, IgH+, CD79a+, CD3−
Nody-1 (132) ascites from alimentary lymphoma patient TCR+, IgH−, CD3+, CD21−
KIT overexpression, also called 
TL-1
Ema (132) pleural fluid from T-cell lymphoma patient TCR+, IgH−, CD3+, CD21−
CLK (132) ascites from T-cell lymphoma patient TCR+, IgH−, CD3−, CD21−
CLC (132) pleural fluid from T-cell lymphoma patient TCR−, IgH−, CD3−, CD21−
3132 (150, 151) ascites from malignant lymphoma patient IgH+ produces retroviral particles?
CLGL-90 (124, 152) LGL T-cell leukemia TCR+, CD3+, CD79a− homozygous CDKN2A deletion
17–71 (124, 152, 153) lymph node from B-cell lymphoma patient TCR−, CD79a+, CD3−, CD21− near tetraploid
OSW (130) pleural fluid from T-cell lymphoma patient TCR+, IgH−, CD3−, CD21−
MYC amplification; PTEN, p16, 
and RB1 deletion
CLL-1390 (124, 152) primitive T-cell leukemia TCR+, CD34+, CD3−, CD21− homozygous PTEN deletion
DLC 01 (128)
lymph node from a Sezary syndrome 
patient CD3+, CD4−, CD8+ produces retroviral particles?
DLC 02 (128)
peripheral blood lymphocytes from an 
LGL patient CD4−, CD8+ produces retroviral particles?
LGL: large granulocytic leukemia
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